Outcomes of patients with double-hit lymphoma who achieve first complete remission

Daniel J. Landsburg, Anthony R. Mato, James N. Gerson, Stefan K. Barta, Marissa K. Falkiewicz, Christina Howlett, Tatyana Feldman, Joseph Maly, Kristie A. Blum, Brian T. Hill, Shaoying Li, L. Jeffrey Medeiros, Pallawi Torka, Francisco Hernandez-Ilizaliturri, Jennifer K. Lue, Jennifer E. Amengual, Nishitha M. Reddy, Arun Singavi, Timothy S. Fenske, Julio C. ChavezJason B. Kaplan, Amir Behdad, Adam M. Petrich, David J. Peace, Sunita Nathan, Martin A. Bast, Julie Marie Vose, Adam J. Olszewski, Cristiana Costa, Frederick Lansigan, Oscar Calzada, Jonathon B. Cohen, Xavier Rivera, Daniel O. Persky, Ryan D. Cassaday

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Purpose Patients with double-hit lymphoma (DHL) rarely achieve long-term survival following disease relapse. Some patients with DHL undergo consolidative autologous stem-cell transplantation (autoSCT) to reduce the risk of relapse, although the benefit of this treatment strategy is unclear. Methods Patients with DHL who achieved first complete remission following completion of front-line therapy with either rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or intensive front-line therapy, and deemed fit for autoSCT, were included. A landmark analysis was performed, with time zero defined as 3 months after completion of front-line therapy. Patients who experienced relapse before or who were not followed until that time were excluded. Results Relapse-free survival (RFS) and overall survival (OS) rates at 3 years were 80% and 87%, respectively, for all patients (n = 159). Three-year RFS and OS rates did not differ significantly for autoSCT (n = 62) versus non-autoSCT patients (n = 97), but 3-year RFS was inferior in patients who received R-CHOP compared with intensive therapy (56% v 88%; P = .002). Three-year RFS and OS did not differ significantly for patients in the R-CHOP or intensive therapy cohorts when analyzed by receipt of autoSCT. The median OS following relapse was 8.6 months. Conclusion In the largest reported series, to our knowledge, of patients with DHL to achieve first complete remission, consolidative autoSCT was not associated with improved 3-year RFS or OS. In addition, patients treated with R-CHOP experienced inferior 3-year RFS compared with those who received intensive front-line therapy. When considered in conjunction with reports of patients with newly diagnosed DHL, which demonstrate lower rates of disease response to R-CHOP compared with intensive front-line therapy, our findings further support the use of intensive front-line therapy for this patient population.

Original languageEnglish (US)
Pages (from-to)2260-2267
Number of pages8
JournalJournal of Clinical Oncology
Volume35
Issue number20
DOIs
StatePublished - Jul 10 2017

Fingerprint

Lymphoma
Stem Cell Transplantation
Recurrence
Survival
Therapeutics
Survival Rate
Vincristine
Prednisone
Doxorubicin
Cyclophosphamide

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Landsburg, D. J., Mato, A. R., Gerson, J. N., Barta, S. K., Falkiewicz, M. K., Howlett, C., ... Cassaday, R. D. (2017). Outcomes of patients with double-hit lymphoma who achieve first complete remission. Journal of Clinical Oncology, 35(20), 2260-2267. https://doi.org/10.1200/JCO.2017.72.2157

Outcomes of patients with double-hit lymphoma who achieve first complete remission. / Landsburg, Daniel J.; Mato, Anthony R.; Gerson, James N.; Barta, Stefan K.; Falkiewicz, Marissa K.; Howlett, Christina; Feldman, Tatyana; Maly, Joseph; Blum, Kristie A.; Hill, Brian T.; Li, Shaoying; Medeiros, L. Jeffrey; Torka, Pallawi; Hernandez-Ilizaliturri, Francisco; Lue, Jennifer K.; Amengual, Jennifer E.; Reddy, Nishitha M.; Singavi, Arun; Fenske, Timothy S.; Chavez, Julio C.; Kaplan, Jason B.; Behdad, Amir; Petrich, Adam M.; Peace, David J.; Nathan, Sunita; Bast, Martin A.; Vose, Julie Marie; Olszewski, Adam J.; Costa, Cristiana; Lansigan, Frederick; Calzada, Oscar; Cohen, Jonathon B.; Rivera, Xavier; Persky, Daniel O.; Cassaday, Ryan D.

In: Journal of Clinical Oncology, Vol. 35, No. 20, 10.07.2017, p. 2260-2267.

Research output: Contribution to journalArticle

Landsburg, DJ, Mato, AR, Gerson, JN, Barta, SK, Falkiewicz, MK, Howlett, C, Feldman, T, Maly, J, Blum, KA, Hill, BT, Li, S, Medeiros, LJ, Torka, P, Hernandez-Ilizaliturri, F, Lue, JK, Amengual, JE, Reddy, NM, Singavi, A, Fenske, TS, Chavez, JC, Kaplan, JB, Behdad, A, Petrich, AM, Peace, DJ, Nathan, S, Bast, MA, Vose, JM, Olszewski, AJ, Costa, C, Lansigan, F, Calzada, O, Cohen, JB, Rivera, X, Persky, DO & Cassaday, RD 2017, 'Outcomes of patients with double-hit lymphoma who achieve first complete remission', Journal of Clinical Oncology, vol. 35, no. 20, pp. 2260-2267. https://doi.org/10.1200/JCO.2017.72.2157
Landsburg DJ, Mato AR, Gerson JN, Barta SK, Falkiewicz MK, Howlett C et al. Outcomes of patients with double-hit lymphoma who achieve first complete remission. Journal of Clinical Oncology. 2017 Jul 10;35(20):2260-2267. https://doi.org/10.1200/JCO.2017.72.2157
Landsburg, Daniel J. ; Mato, Anthony R. ; Gerson, James N. ; Barta, Stefan K. ; Falkiewicz, Marissa K. ; Howlett, Christina ; Feldman, Tatyana ; Maly, Joseph ; Blum, Kristie A. ; Hill, Brian T. ; Li, Shaoying ; Medeiros, L. Jeffrey ; Torka, Pallawi ; Hernandez-Ilizaliturri, Francisco ; Lue, Jennifer K. ; Amengual, Jennifer E. ; Reddy, Nishitha M. ; Singavi, Arun ; Fenske, Timothy S. ; Chavez, Julio C. ; Kaplan, Jason B. ; Behdad, Amir ; Petrich, Adam M. ; Peace, David J. ; Nathan, Sunita ; Bast, Martin A. ; Vose, Julie Marie ; Olszewski, Adam J. ; Costa, Cristiana ; Lansigan, Frederick ; Calzada, Oscar ; Cohen, Jonathon B. ; Rivera, Xavier ; Persky, Daniel O. ; Cassaday, Ryan D. / Outcomes of patients with double-hit lymphoma who achieve first complete remission. In: Journal of Clinical Oncology. 2017 ; Vol. 35, No. 20. pp. 2260-2267.
@article{35bde7caba124765980e257381165a3d,
title = "Outcomes of patients with double-hit lymphoma who achieve first complete remission",
abstract = "Purpose Patients with double-hit lymphoma (DHL) rarely achieve long-term survival following disease relapse. Some patients with DHL undergo consolidative autologous stem-cell transplantation (autoSCT) to reduce the risk of relapse, although the benefit of this treatment strategy is unclear. Methods Patients with DHL who achieved first complete remission following completion of front-line therapy with either rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or intensive front-line therapy, and deemed fit for autoSCT, were included. A landmark analysis was performed, with time zero defined as 3 months after completion of front-line therapy. Patients who experienced relapse before or who were not followed until that time were excluded. Results Relapse-free survival (RFS) and overall survival (OS) rates at 3 years were 80{\%} and 87{\%}, respectively, for all patients (n = 159). Three-year RFS and OS rates did not differ significantly for autoSCT (n = 62) versus non-autoSCT patients (n = 97), but 3-year RFS was inferior in patients who received R-CHOP compared with intensive therapy (56{\%} v 88{\%}; P = .002). Three-year RFS and OS did not differ significantly for patients in the R-CHOP or intensive therapy cohorts when analyzed by receipt of autoSCT. The median OS following relapse was 8.6 months. Conclusion In the largest reported series, to our knowledge, of patients with DHL to achieve first complete remission, consolidative autoSCT was not associated with improved 3-year RFS or OS. In addition, patients treated with R-CHOP experienced inferior 3-year RFS compared with those who received intensive front-line therapy. When considered in conjunction with reports of patients with newly diagnosed DHL, which demonstrate lower rates of disease response to R-CHOP compared with intensive front-line therapy, our findings further support the use of intensive front-line therapy for this patient population.",
author = "Landsburg, {Daniel J.} and Mato, {Anthony R.} and Gerson, {James N.} and Barta, {Stefan K.} and Falkiewicz, {Marissa K.} and Christina Howlett and Tatyana Feldman and Joseph Maly and Blum, {Kristie A.} and Hill, {Brian T.} and Shaoying Li and Medeiros, {L. Jeffrey} and Pallawi Torka and Francisco Hernandez-Ilizaliturri and Lue, {Jennifer K.} and Amengual, {Jennifer E.} and Reddy, {Nishitha M.} and Arun Singavi and Fenske, {Timothy S.} and Chavez, {Julio C.} and Kaplan, {Jason B.} and Amir Behdad and Petrich, {Adam M.} and Peace, {David J.} and Sunita Nathan and Bast, {Martin A.} and Vose, {Julie Marie} and Olszewski, {Adam J.} and Cristiana Costa and Frederick Lansigan and Oscar Calzada and Cohen, {Jonathon B.} and Xavier Rivera and Persky, {Daniel O.} and Cassaday, {Ryan D.}",
year = "2017",
month = "7",
day = "10",
doi = "10.1200/JCO.2017.72.2157",
language = "English (US)",
volume = "35",
pages = "2260--2267",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "20",

}

TY - JOUR

T1 - Outcomes of patients with double-hit lymphoma who achieve first complete remission

AU - Landsburg, Daniel J.

AU - Mato, Anthony R.

AU - Gerson, James N.

AU - Barta, Stefan K.

AU - Falkiewicz, Marissa K.

AU - Howlett, Christina

AU - Feldman, Tatyana

AU - Maly, Joseph

AU - Blum, Kristie A.

AU - Hill, Brian T.

AU - Li, Shaoying

AU - Medeiros, L. Jeffrey

AU - Torka, Pallawi

AU - Hernandez-Ilizaliturri, Francisco

AU - Lue, Jennifer K.

AU - Amengual, Jennifer E.

AU - Reddy, Nishitha M.

AU - Singavi, Arun

AU - Fenske, Timothy S.

AU - Chavez, Julio C.

AU - Kaplan, Jason B.

AU - Behdad, Amir

AU - Petrich, Adam M.

AU - Peace, David J.

AU - Nathan, Sunita

AU - Bast, Martin A.

AU - Vose, Julie Marie

AU - Olszewski, Adam J.

AU - Costa, Cristiana

AU - Lansigan, Frederick

AU - Calzada, Oscar

AU - Cohen, Jonathon B.

AU - Rivera, Xavier

AU - Persky, Daniel O.

AU - Cassaday, Ryan D.

PY - 2017/7/10

Y1 - 2017/7/10

N2 - Purpose Patients with double-hit lymphoma (DHL) rarely achieve long-term survival following disease relapse. Some patients with DHL undergo consolidative autologous stem-cell transplantation (autoSCT) to reduce the risk of relapse, although the benefit of this treatment strategy is unclear. Methods Patients with DHL who achieved first complete remission following completion of front-line therapy with either rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or intensive front-line therapy, and deemed fit for autoSCT, were included. A landmark analysis was performed, with time zero defined as 3 months after completion of front-line therapy. Patients who experienced relapse before or who were not followed until that time were excluded. Results Relapse-free survival (RFS) and overall survival (OS) rates at 3 years were 80% and 87%, respectively, for all patients (n = 159). Three-year RFS and OS rates did not differ significantly for autoSCT (n = 62) versus non-autoSCT patients (n = 97), but 3-year RFS was inferior in patients who received R-CHOP compared with intensive therapy (56% v 88%; P = .002). Three-year RFS and OS did not differ significantly for patients in the R-CHOP or intensive therapy cohorts when analyzed by receipt of autoSCT. The median OS following relapse was 8.6 months. Conclusion In the largest reported series, to our knowledge, of patients with DHL to achieve first complete remission, consolidative autoSCT was not associated with improved 3-year RFS or OS. In addition, patients treated with R-CHOP experienced inferior 3-year RFS compared with those who received intensive front-line therapy. When considered in conjunction with reports of patients with newly diagnosed DHL, which demonstrate lower rates of disease response to R-CHOP compared with intensive front-line therapy, our findings further support the use of intensive front-line therapy for this patient population.

AB - Purpose Patients with double-hit lymphoma (DHL) rarely achieve long-term survival following disease relapse. Some patients with DHL undergo consolidative autologous stem-cell transplantation (autoSCT) to reduce the risk of relapse, although the benefit of this treatment strategy is unclear. Methods Patients with DHL who achieved first complete remission following completion of front-line therapy with either rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or intensive front-line therapy, and deemed fit for autoSCT, were included. A landmark analysis was performed, with time zero defined as 3 months after completion of front-line therapy. Patients who experienced relapse before or who were not followed until that time were excluded. Results Relapse-free survival (RFS) and overall survival (OS) rates at 3 years were 80% and 87%, respectively, for all patients (n = 159). Three-year RFS and OS rates did not differ significantly for autoSCT (n = 62) versus non-autoSCT patients (n = 97), but 3-year RFS was inferior in patients who received R-CHOP compared with intensive therapy (56% v 88%; P = .002). Three-year RFS and OS did not differ significantly for patients in the R-CHOP or intensive therapy cohorts when analyzed by receipt of autoSCT. The median OS following relapse was 8.6 months. Conclusion In the largest reported series, to our knowledge, of patients with DHL to achieve first complete remission, consolidative autoSCT was not associated with improved 3-year RFS or OS. In addition, patients treated with R-CHOP experienced inferior 3-year RFS compared with those who received intensive front-line therapy. When considered in conjunction with reports of patients with newly diagnosed DHL, which demonstrate lower rates of disease response to R-CHOP compared with intensive front-line therapy, our findings further support the use of intensive front-line therapy for this patient population.

UR - http://www.scopus.com/inward/record.url?scp=85023764940&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85023764940&partnerID=8YFLogxK

U2 - 10.1200/JCO.2017.72.2157

DO - 10.1200/JCO.2017.72.2157

M3 - Article

C2 - 28475457

AN - SCOPUS:85023764940

VL - 35

SP - 2260

EP - 2267

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 20

ER -